Information Provided By:
Fly News Breaks for April 26, 2016
ALXN
Apr 26, 2016 | 08:00 EDT
Oppenheimer analyst Christopher Marai recommends owning Alexion's shares as he expects the launching of Strensiq and Kanuma to drive revenues into the second half of 2016 and beyond, supporting valuation upside in the next 12 months. The analyst reiterates an Outperform rating and $228 price target on the shares.
News For ALXN From the Last 2 Days
There are no results for your query ALXN